DuPont's diversified turnover up 9%:
This article was originally published in Clinica
US conglomerate DuPont has reported 9% growth in revenues for its diversified businesses to $3,339 million in the first half of the year. This division includes DuPont's imaging and diagnostics operations which were put up for sale in May (see Clinica No 656, p 11). Dupont's total first-half sales increased 12% to $21,578 million and net income rose 32% to $1,897 million.
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.